Creon® (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer

A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects.

Clinical Setting

Subjects with moderate to severe Exocrine Pancreatic Insufficiency due to pancreatic cancer.

Study Description

Evaluate the effects of 2 different dose levels of pancrelipase (pancreatic enzymes) on dietary fat absorption and exocrine pancreatic insufficiency (EPI) symptoms in subjects with pancreatic cancer and EPI.